Figure 3
From: Specifically targeting ERK1 or ERK2 kills Melanoma cells
![Figure 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1479-5876-10-15/MediaObjects/12967_2012_Article_999_Fig3_HTML.jpg)
ERK1 and/or ERK2 shRNA triggers caspase cascade including PARP cleavage, and caspase inhibitor partial block of killing of A375 cells. A. Western blot analysis of caspase 3, caspase 8 and PARP including both intact (inactive) and cleaved (active) forms in A375 cells on days 2, 4 and 6 following exposure to shRNAs. GAPDH confirms equivalent loading. B). Addition of pan-caspase inhibitor, ZVAD (20 mM; last 2 days) reduces killing of A375 cells triggered by ERK1 and/or ERK2 shRNA. Histograms represent the means +/- SEM from 3 independent experiments. Statistical significance portrayed as follows: *p < 0.01, **p < 0.02, ***p < 0.002.